Tags

Type your tag names separated by a space and hit enter

Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help?
Gynecol Oncol 2014; 132(1):248-53GO

Abstract

Current data indicate that there is a significant risk of endometrial cancer (EC) in women with polycystic ovarian syndrome (PCOS), although further research needed to clarify the exact molecular mechanisms. Endometrial hyperplasia is a premalignant condition that usually heralds EC and it shares identical risk factors with EC. Metabolic syndrome with a triad of obesity, hyperinsulinaemia and diabetes, which is commonly observed in PCOS appears to be a key mechanism in EC pathogenesis. Measures to improve insulin resistance could therefore play a role in reducing the risk of EC in women with PCOS. Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes. It has been clearly shown in both animal and human studies that metformin is of value in reversing endometrial hyperplasia. Metformin may therefore prevent EC in PCOS. This article reviews the use of metformin in reducing EC risk in PCOS and makes a case for future research on this topic.

Authors+Show Affiliations

The Division of Obstetrics and Gynaecology and Child Health, School of Medicine, D Floor, East Block, Queen's Medical Centre, Nottingham University Hospital NHS Trust, Derby Road, NG7 2UH, United Kingdom; The Department of Obstetrics and Gynaecology, Faculty of Medicine, UKM Medical Centre, Kuala Lumpur, 56000, Malaysia. Electronic address: mgxmnsh@nottingham.ac.uk.The Division of Obstetrics and Gynaecology and Child Health, School of Medicine, D Floor, East Block, Queen's Medical Centre, Nottingham University Hospital NHS Trust, Derby Road, NG7 2UH, United Kingdom.The Department of Obstetrics and Gynaecology, Faculty of Medicine, UKM Medical Centre, Kuala Lumpur, 56000, Malaysia.The Department of Obstetrics and Gynaecology, City Hospital, Hucknall Road, NG5 1PB, United Kingdom.Centre of Excellence for Autoimmunity in Cancer, School of Graduate Entry Medicine and Health, University of Nottingham, NG5 1PB, United Kingdom.Department of Histopathology, A Floor, East Block, Queen's Medical Centre, Nottingham University Hospital NHS Trust, United Kingdom.The Department of Obstetrics and Gynaecology, City Hospital, Hucknall Road, NG5 1PB, United Kingdom.Centre for Analytical Bioscience, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, United Kingdom.The School of Molecular Biology, Clinical Sciences Building, University of Nottingham, Hucknall Road, NG5 1PB, United Kingdom.The Division of Obstetrics and Gynaecology and Child Health, School of Medicine, D Floor, East Block, Queen's Medical Centre, Nottingham University Hospital NHS Trust, Derby Road, NG7 2UH, United Kingdom.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

24183733

Citation

Shafiee, Mohamad Nasir, et al. "Preventing Endometrial Cancer Risk in Polycystic Ovarian Syndrome (PCOS) Women: Could Metformin Help?" Gynecologic Oncology, vol. 132, no. 1, 2014, pp. 248-53.
Shafiee MN, Khan G, Ariffin R, et al. Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? Gynecol Oncol. 2014;132(1):248-53.
Shafiee, M. N., Khan, G., Ariffin, R., Abu, J., Chapman, C., Deen, S., ... Atiomo, W. (2014). Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? Gynecologic Oncology, 132(1), pp. 248-53. doi:10.1016/j.ygyno.2013.10.028.
Shafiee MN, et al. Preventing Endometrial Cancer Risk in Polycystic Ovarian Syndrome (PCOS) Women: Could Metformin Help. Gynecol Oncol. 2014;132(1):248-53. PubMed PMID: 24183733.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help? AU - Shafiee,Mohamad Nasir, AU - Khan,Gulafshana, AU - Ariffin,Rina, AU - Abu,Jafaru, AU - Chapman,Caroline, AU - Deen,Suha, AU - Nunns,David, AU - Barrett,David A, AU - Seedhouse,Claire, AU - Atiomo,William, Y1 - 2013/10/30/ PY - 2013/08/23/received PY - 2013/10/11/revised PY - 2013/10/22/accepted PY - 2013/11/5/entrez PY - 2013/11/5/pubmed PY - 2014/4/25/medline KW - Endometrial cancer KW - Endometrial hyperplasia KW - Metformin KW - PCOS SP - 248 EP - 53 JF - Gynecologic oncology JO - Gynecol. Oncol. VL - 132 IS - 1 N2 - Current data indicate that there is a significant risk of endometrial cancer (EC) in women with polycystic ovarian syndrome (PCOS), although further research needed to clarify the exact molecular mechanisms. Endometrial hyperplasia is a premalignant condition that usually heralds EC and it shares identical risk factors with EC. Metabolic syndrome with a triad of obesity, hyperinsulinaemia and diabetes, which is commonly observed in PCOS appears to be a key mechanism in EC pathogenesis. Measures to improve insulin resistance could therefore play a role in reducing the risk of EC in women with PCOS. Metformin is an insulin sensitising agent which is safe, widely available and currently licensed for type-2 diabetes. It has been clearly shown in both animal and human studies that metformin is of value in reversing endometrial hyperplasia. Metformin may therefore prevent EC in PCOS. This article reviews the use of metformin in reducing EC risk in PCOS and makes a case for future research on this topic. SN - 1095-6859 UR - https://www.unboundmedicine.com/medline/citation/24183733/Preventing_endometrial_cancer_risk_in_polycystic_ovarian_syndrome__PCOS__women:_could_metformin_help L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(13)01277-8 DB - PRIME DP - Unbound Medicine ER -